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1. Introduction 
Osteoarthritis (OA) is a degenerative joint disease characterized by deterioration in the 
integrity of hyaline cartilage and subchondral bone (Ishiguro et al., 2002). OA is the most 
common articular pathology and the most frequent cause of disability. Genetic, metabolic 
and physical factors interact in the pathogenesis of OA producing cartilage damage. The 
incidence of OA is directly related to age and is expected to increase along with the median 
age of the population (Brooks, 2002). 
The capacity for the self-repair of articular cartilage is very limited, mainly because it is an 
avascular tissue (Mankin, 1982; Resinger et al., 2004; Fuentes-Boquete et al., 2008). 
Consequently, progenitor cells in blood and marrow cannot enter the damaged region to 
influence or contribute to the reparative process (Steinert et al., 2007).  
There are a lack of reliable techniques and methods to stimulate growth of new tissue to 
treat degenerative diseases and trauma (Wong et al., 2005).  
Modalities of cellular therapy to repair focal articular cartilage defects include the 
implantation of cells with chondrogenic capacity (Koga et al., 2008) and creating access to 
the bone-marrow. Of the numerous treatments available nowadays, no technique has yet 
been able to consistently regenerate normal hyaline cartilage. Current treatments generate a 
fibrocartilaginous tissue that is different from hyaline articular cartilage. To avoid the need 
for prosthetic replacement, different cell treatments have been developed with the aim of 
forming a repair tissue with structural, biochemical, and functional characteristics 
equivalent to those of natural articular cartilage (Fuentes-Boquete et al., 2007). This review 
summarizes the options for treatment of articular cartilage defects from both the 
experimental and clinical perspective (Fig. 1). 
2. Perforation of the subchondral bone 
This treatment is one of the most popular marrow-stimulating techniques based on the 
principle of inducing invasion of mesenchymal progenitor cells from the underlying 
subchondral bone to the lesion site, in order to initiate cartilage repair (Pelttari et al., 2009). 
This minimally invasive procedure has a low cost and is currently being used as the first 
treatment in patients not treated of cartilage defects. When the defect affecting the cartilage 
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penetrates to the bone and bone marrow spaces (osteochondral injury), mesenchymal cells 
from the bone marrow migrate with the hemorrhage and remain in the blood clot filling the 
defect, and are differentiated into articular chondrocytes thus been responsible for the repair 
of the defect (Fig. 2) (Shapiro et al., 1993). The opening of subchondral vascular spaces is 
utilized for several surgical strategies, such as arthroscopic abrasion (Friedman et al., 1984), 
subchondral drilling (Muller & Kohn, 1999), spongialization (Ficat et al., 1979) and 
microfracture (which produces the best results) (Steadman et al., 1999). In most cases, bone 
is formed in the bony defect and fibrocartilaginous tissue is formed in the chondral lesion 
(Johnson, 1986; Buckwalter & Mankin, 1998). In the case of large osteochondral defects, the 
ability to spontaneously repair the damage is negligible. On the contrary, if the chondral 
defect is small, articular cartilage can be completely repaired in full. The critical size of the 













Fig. 1. Different treatments of articular cartilage defects. 
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The outcome of these procedures is highly variable and frequently results in repair tissue 
composed of fibrocartilage with some limitations in quality and duration as compared to 
native hyaline cartilage (Pelttari et al., 2009). Experimental studies in rabbits (Metsaranta et 
al., 1996; Menche et al., 1996) and dogs (Altman et al., 1992) have shown that the repair 
tissue generated by these processes is fibrocartilaginous in nature, differing from hyaline 
articular cartilage in biochemical composition, structural organization, durability and 
biomechanical properties, and degenerates over time (Shapiro et al., 1993; Menche et al., 
1996). In addition, the newly formed subchondral bone is thicker than the native 
subchondral bone (Qiu et al., 2003). The co-expression of types I and II collagens in repair 
tissue does not occur until one year following subchondral penetration (Furukawa et al., 
1980). Clinical results, to some degree, contradict the findings relating to the quality of the 
repair tissue. For example, the treatment of knee osteochondral defects by microfracture has 
provided good clinical results after two years (Knutsen et al., 2004). This longevity, 
however, seems to be age-dependent, with the most persistent repair cartilage in patients 
under the age of 40 (Kreuz et al., 2006a). Although the initiation of a degenerative process 
for tissue repair has been described at 18 months after microfracture (Kreuz et al., 2006b), 
and 7 to 17 years after microfracture, improvement in articular function and pain relief were 









Fig. 2. Types of articular cartilage defects. In a partial defect the lesion includes cartilage 
tissue and part of the subchondral bone [A]. In a deep defect the lesion extends to the bone 
marrow [B]. C, uncalcified articular cartilage; t, tidemark; cc, calcified articular cartilage; sb, 
subchondral bone; bm, bone marrow. 
3. Implants of periosteum and perichondrium 
Tissue grafts have potential benefits since they allow the introduction of a new cell 
population embedded in an organic matrix, and reduces the development of fibrous 
adhesions between the articular surfaces before forming a new articular surface.  
Periosteum and perichondrium contain mesenchymal stem cells (MSCs) that are capable of 
chondrogenesis (O´Driscoll et al., 2001; Duynstee et al., 2002). In particular, periosteum 
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consists of a fibrous outer layer, containing fibroblasts; and an inner layer or cambium, in 
direct contact with the bone, of higher cellular density, which contains MSCs.  
Experimental studies in rabbits, indicated that the grafts of periosteum and perichondrium 
produce an incomplete filling of the chondral defect, and showed no significant differences 
between the two grafts in the quality of the repair tissue (Carranza-Bencano et al., 1999). In 
contrast, in a horse model, it was observed that chondrogenesis was more frequent and of 
greater magnitude in the grafts of periosteum than in perichondrium (Vachon et al., 1989). 
In both cases, these membrane implants forms a fibrocartilaginous repair tissue that does 
not seem to mature over time (Dounchis et al., 2000; Trzeciak et al., 2006). However, the 
clinical effects of a perichondrium implant are similar those of subchondral perforation. At 
10 years following either procedure there were no significant differences observed between 
their outcomes (Bouwmeester et al., 2002). However, the graft of perichondrium requires an 
additional intervention.  
With age, decreases the chondrogenic potential of periosteum, decreasing the ability of 
MSCs to proliferate and differentiate into chondrocytes (O´Driscoll et al., 2001). This 
procedure has confirmed the improvement of joint function and pain relief (Korkala & 
Kuokkanen, 1995). The periosteum has the advantage of being readily available for 
transplantation. However, the technique of obtaining and management of periosteum is a 
critical step and determining the chondrogenic potential; if the cambium layer is not 
preserved, the procedure fails (O´Driscoll & Fitzsimmons, 2000). 
At present, there is no sufficient evidence to justify the use periosteum and perichondrium 
implants in the treatment of chondral defects. 
4. Osteoperiosteal implants 
The cylinder of bone graft covered with periosteum has been used for the treatment of 
osteochondral defects. Although it has been reported that its clinical application produces 
improved joint function and pain relief (Korkala & Kuokkanen, 1995), studies in animals 
show a neosynthesized tissue with fibrous features (van Susante et al., 2003). When the graft 
is accompanied by chondrogenic inductors it acquires a fibrocartilaginous appearance (Jung 
et al., 2005). Also, bleeding from bone marrow spaces from the injury probably interferes 
with the repair action of the periosteum germ layer.  In fact, in a rabbit model of 
osteoperiosteal implant it was found that nearly 67% of repair tissue cells were derived 
mainly from the bone marrow (Zarnett & Salter, 1989). 
Osteochondral grafts have the advantage of providing matrix and viable chondrocytes that 
maintain this matrix (Czitrom et al., 1990; Schachar et al., 1992; Ohlendorf et al., 1996). In 
addition, it is possible to retrieve the subchondral bone and the contour of the joint of 
patients with osteochondral defects or articular incongruity. The articular cartilage 
transplantation as part of an osteochondral graft provides the decrease in joint pain (Beaver 
et al., 1992), perhaps by the replacement of the innervated area of the subchondral bone by a 
graft without innervation. 
5. Mosaicplasty 
Autologous mosaicplasty is considered to be a promising alternative for treatment of small 
to medium-sized focal chondral and osteochondral defects (Bartha et al., 2006). This 
technique involves the translocation of osteochondral cylinders, or plugs, from a low-
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weight-bearing normal site to a high-weightbearing diseased site. The injured area is 
completely covered by means of the combination of different sizes of cylinders (Szerb et al., 
2005). The donor sites spontaneously repair with mesenchymal stromal cells from the bone 
marrow to promote a new fibrocartilaginous tissue. 
This procedure, which clinical application started in 1992 (Hangody & Karpati, 1994; 
Hangody et al., 2001) is considered a promising alternative for the treatment of chondral 
and osteochondral defects of small and medium-size load in synovial joints (Bartha et al., 
2006). However, it is limited by several factors. The ideal diameter of the defect should 
range between 1 and 4 cm2. In addition, clinical experience shows that age is a limiting 
factor, it is recommended to apply this technique only for patients under 50 years. 
Contraindications to the use of mosaicplasty include infection, tumor and rheumatoid 
arthritis (Szerb et al., 2005). 
Arthroscopic evaluations at 5 (Chow et al., 2004) and 10 years (Hangody & Fules, 2003) after 
osteochondral cylinder implantation showed survival of the transplanted articular cartilage, 
congruency between opposing (treated and untreated) joint surfaces and fibrocartilaginous 
repair of the donor sites. However, if the osteochondral cylinders protrude above the 
surface, joint problems can arise. At 4 months post-surgery, patients with protruding 
cylinders experienced a “catching sensation” and some of these patients reported joint pain. 
Arthroscopic examinations of these cases revealed fissures in the osteochondral cylinders 
and fibrillation around the recipient site (Nakagawa et al., 2007). 
The use of autologous mosaicplasty is limited by the defect size, which determines the 
number of osteochondral cylinders required. Thus, in large defects the best option is 
osteochondral allogenic transplantation. In addition, the implanted tissue comes from an 
area of low load, showing a thin thickness, a different histological structure and, therefore, a 
lower functional capacity for dealing with charge absorption. 
The articular cartilage produced by this technique exhibits topographical variations in 
morphological, biochemical and physical properties (Xia et al., 2002; Rogers et al., 2006). 
Because the implanted tissue is harvested from a low-weight-bearing area, the cartilage is 
thinner and differs in histological structure from cartilage from high weight-bearing areas 
(Fragonas et al., 1998; Gomez et al., 2000). 
6. Osteoarticular allotransplantation 
Due to the avascular nature of chondrocytes and the fact that they are encapsulated in the  
extracellular matrix (ECM), articular cartilage is considered a privileged immunological 
tissue (Langer & Gross, 1974). Thus, the allogenic transplant may be the solution for 
problems arising from the autologous mosaicplasty (avoiding injury to the low load zone of 
cartilage, can produce a large number of osteochondral cylinders and these can come from 
the same load area). In fact, osteochondral allograft in knee has shown a good integration 
and provides a functional improvement at 2 years (McCulloch et al., 2007), showing a 85% 
of implant survival after more than 10 years after intervention (Gross et al., 2005). 
7. Autologous chondrocyte implantation 
A cell-based therapeutic alternative offering more effective repair of focal articular cartilage 
defects is autologous chondrocyte implantation (ACI) which was developed in a rabbit 
experimental model (Grande et al., 1987 & 1989). The first clinical application of this method 
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was performed by the group of Brittberg (Brittberg et al., 1994), which also demonstrated 
the successful repair of articular cartilage in rabbits transplanted with autologous 
chondrocytes (Brittberg et al., 1996). Currently the autologous chondrocyte implantation is a 
safe and effective therapeutic alternative to repair focal articular cartilage lesions (Pérez-
Cachafeiro et al., 2010; Brittberg et al., 1994; Richardson et al., 1999; Peterson et al., 2000; 
Roberts et al., 2001). This procedure is also used for patients with osteochondritis dissecans 
(Peterson et al., 2002), but not for osteoarthritis joints. Because the results of this technique 
are highly age-dependent, the use of this procedure is recommended for patients younger 
than 55 years of age. The technique involves obtaining, by arthroscopy, articular cartilage 
explants from low-weight-bearing areas. Chondrocytes are then isolated and expanded in 
vitro to obtain a sufficient number of cells (approximately 10-12x106 cells) to introduce into 
the defect site, where they are expected to synthesize new cartilaginous matrix. In a second 
surgical intervention, the periosteum of the patient is removed from the proximal extremity 
and sutured to the edge of the cartilage injury, guiding the cambium layer towards de 
defect. This will close the defect cavity to retain the suspension of chondrocytes. Then, 
chondrocytes of the patient are resuspended in a liquid medium and injected into the cavity. 
A recent study assessed the efficacy and safety of ACI in 111 patients and demonstrated 
good clinical results in about 70%of the cases after 3 to 5 years (Pérez-Cachafeiro et al., 
2010). Sometimes these autologous articular chondrocytes are introduced into the defect site 
as a cell suspension or in association with a supportive matrix (matrix-assisted ACI, MACI) 
(Pelttari et al., 2009). MACI uses a cell-seeded collagen matrix for treatment of cartilage 
defects. A prospective clinical investigation carried out in 38 patients with localized cartilage 
defects for a period of up to 5 years after surgery, showed that MACI represents a viable 
alternative for treatment of local cartilage defects of the knee (Behrens et al., 2006). 
The outcome of these chondrocyte-based techniques is generally quite good (Minas, 2001; 
Peterson et al., 2000) but in many cases results in the formation of non-hyaline cartilage 
repair tissue with inferior mechanical properties and limited durability (Pelttari et al., 2009). 
ACI has several technical limitations: a) obtaining cartilage explants requires an additional 
surgical intervention, adding to the articular cartilage damage that increases the 
osteoarthritic process (Marcacci et al., 2002); b) in vitro chondrocyte proliferation must be 
limited because the capacity to produce stable cartilage in vivo is gradually reduced when 
cell divisions are increased (Dell´Accio et al., 2001); c) aging reduces the cellular density of 
the cartilage, which impacts chondrocyte proliferation capacity in vitro (Menche et al., 1998) 
and the chondrogenic potential of the periosteum (O´Driscoll & Fitzsimmons, 2001), d) cell 
culture procedures take too long (3 to 6 weeks) and increase the risk of contamination, e) risk 
of leakage of transplanted chondrocytes from the cartilage defects, f) the effects of gravity 
causing the chondrocytes to sink to the dependent side of the defect, resulting in an unequal 
distribution of cells that hampers the homogenous regeneration of the cartilage (Díaz-Prado 
et al., 2010c; Sohn et al., 2002), g) not the least the reacquisition of phenotypes of 
dedifferentiated chondrocytes in a monolayer culture (Kimura et al., 1984; Benya & Shaffer, 
1982) and h) hypertrophy of tissue (Steinwachs & Kreuz, 2007; Haddo et al., 2004). The use 
of periosteum membrane poses constraints and the need for wide surgical incision, 
hypertrophy of the periosteum peripheral implant and its potential for ectopic calcification. 
As an alternative it has been proposed the use of a membrane collagen type I/III (Haddo et 
al., 2004; Krishnan et al., 2006; Robertson et al., 2007). The use of both kinds of membranes 
shows no significant differences in the clinical assessment, although arthroscopic analysis 
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showed that after implantation of periosteum a substantial number of patients required a 
cleanup of the peripheral hypertrophy (Gooding et al., 2006). 
In 1997, the American Society FDA (Food and Drug Administration) approved the cellular 
technology that uses autologous chondrocytes to repair articular cartilage lesions in the 
knee. This was the first type of cellular technology that was regulated by the industry for 
use in human transplantation (Brittberg et al., 2001). 
The first article about ACI in humans appeared in 1994 (Brittberg et al., 1994). Clinical and 
arthroscopic evaluations of femoral implants showed good results after 2 years and the 
histological study of biopsies of the new tissue showed a similar appearance to hyaline 
cartilage in 11 of 15 cases of femoral implant. From this first approach further studies, based 
on clinical or arthroscopic evaluations, have demonstrated the durability of the implant. 
Thereby, after 5-11 years of treatment showed good or excellent clinical results in 51 of the 
61 patients (Peterson et al., 2002). Histological analysis of the de novo formed tissue revealed 
some heterogeneity in the quality of the repair tissue. Of the 41 biopsies obtained one year 
following implantation, 10% consisted of hyaline cartilage; 24% consisted of a mixture of 
hyaline cartilage and fibrocartilage; 61% were entirely fibrocartilage and 5% consisted only 
of fibrous tissue (Tins et al., 2005). 
Other studies at one year after implantation have shown that fibrocartilaginous morphology 
regions and hyaline morphology regions coexist in the same biopsy; both types having 
proteoglycans and type II collagen (Richardson et al., 1999; Roberts et al., 2001). 
Furthermore, aggrecanase activity was higher than metalloprotease activities in the 
fibrocartilaginous regions although both enzymes were found (Roberts et al., 2001). The 
expression of type IIA and IIB collagen mRNA was also detected (Briggs et al., 2003). These 
mRNA expressions seem be characteristic of the prechondrocytic state (type IIA) and 
differentiated chondrocytes (type IIB) (Nah et al., 2001). These results suggest that ACI 
induces the regeneration of articular cartilage, probably by the turnover and remodelling 
from an initial fibrocartilaginous matrix using enzymatic degradation and synthesis of type 
II collagen (Roberts et al., 2001). It is believed that this process continues for more than 24 
months following the implantation (Peterson et al., 2000, Bentley et al., 2003) and takes place 
in three specific stages: cell proliferation (the first 6 weeks), transition (7 to 26 weeks) and 
remodeling (beyond 27 weeks) (Minas & Peterson, 1997). 
8. Allotransplantation and xenotransplantation of chondrocytes 
Other therapeutic alternatives are allotransplantation (Wakitani et al., 1989; Rahfoth et al., 
1998; Schreiber et al., 1999) and xenotransplantation of chondrocytes (Fuentes-Boquete et al., 
2004, Ramallal et al., 2004), that elude the damage added to the joint during 
autotransplantation to obtain isolated chondrocytes. Allotransplantation is constrained by 
the necessity for compatible donors and limitations on storage of cartilage or chondrocytes 
because cryopreservation reduces survival and proliferation of chondrocytes (Rendal-
Vázquez et al., 2001). Xenotransplantation may resolve some of these problems, but this 
therapeutic alternative has rarely been investigated. The immune barrier is an important 
objection to the use of both of these therapeutic procedures, although its application in 
articular cartilage presents fewer difficulties than in other tissues. Even though isolated 
chondrocytes result in immunogenic reaction, alloimplantation of chondrocytes 
encapsulated in their ECM (Schreiber et al., 1999) or embedded in collagen gel (Wakitani et 
al., 1989) or agarose (Rahfoth et al., 1998) resulted in few or no rejection reactions. Notably, 
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xenotransplantation in vivo of cultured pig chondrocytes into rabbit chondral defects closed 
with periosteal membrane no signs of infiltration by immune cells (Ramallal et al., 2004). 
9. Mesenchymal stem cells transplantation 
Within the bone marrow stroma, a subset of non-hematopoietic cells referred to as MSCs 
exists. These cells can be isolated by adherence to plastic, expanded ex vivo and induced, 
both in vitro or in vivo, to terminally differentiate into multiple mesoderm-type lineages, 
including osteocytes, chondrocytes, adipocytes, tenocytes, myotubes, astrocytes and 
hematopoietic-supporting stroma (Barlow et al., 2008; Minguell et al., 2000; Caplan, 1991) 
and also into cell types of ectodermal (e.g., neurons) and endodermal (e.g., hepatocytes) 
origin (Pasquinelli et al., 2007). Furthermore, MSCs from different tissue sources can have 
biologic distinctions. For example, MSCs derived from bone marrow show a higher 
potential for osteogenic differentiation (Muraglia et al., 2000), while MSCs of synovial origin 
show a greater tendency toward chondrogenic differentiation (Djouad et al., 2005). Under 
identical culture conditions for differentiation, MSCs isolated from the synovial membrane 
show more chondrogenic potential than those derived from bone marrow, periosteum, 
skeletal muscle or adipose tissue (Sakaguchi et al., 2005). Studies of cartilage injury repair in 
animal models using MSCs embedded in collagen gel (Wakitani et al., 1989) or injected into 
defects closed with periosteal membrane (Im et al., 2001) indicate that MSCs can 
differentiate in vivo into a number of cell types in different biologic environments. 
This procedure uses cells isolated from small tissue samples, proliferated in culture, to 
obtain the appropriate number for clinical applications. They can be implanted in the donor 
patient, obviating rejection problems. MSCs may be a tool for tissue repair that has the 
advantage of avoiding the problem of immunological rejection of the allotransplant and the 
ethical conflict of using embryonic stem cells. The recent use of autologous or allogenic stem 
cells has been suggested as an alternative therapeutic approach for treatment of cartilage 
defects (Jung et al., 2009). MSCs have the capability to self-renew and are responsible for 
repair and repopulation of damaged tissues in the adult (Hombach-Klonisch et al., 2008). 
For these reasons MSCs are a promising cell resource for tissue engineering and cell-based 
therapies (Pittenger, 2008). The interest in MSCs and their possible application in cell 
therapy have resulted in a better understanding of the basic biology of these cells. Due to the 
low number of MSCs that can be isolated from a tissue sample, culture expansion is 
necessary to obtain adequate cell numbers for clinical purposes and for the analysis of 
molecular mechanisms. However, the number of mitotic divisions of MSCs in culture must 
be limited because MSCs age during in vitro culture, causing a reduction in their 
proliferative capacity (Banfi et al., 2000; Bonab et al., 2006) and gradual loss of the potential 
for multiple differentiation (Banfi et al., 2000; Izadpanah et al., 2006). The conservation of 
phenotype and differentiation capacity of MSCs are proportional to telomerization 
(Abdallah et al., 2005). Telomeres are normally shortened in successive cell divisions, 
however, in embryonic stem cells the telomere length is restored by telomerase enzyme 
activity. On the other hand, MSCs lack (Zimmermann et al., 2003) adequate levels of 
telomerase activity to achieve telomeric restoration (Izadpanah et al., 2006; Parsch et al., 
2004; Yanada et al., 2006). Patient age also influences the characteristics of MSCs because 
their proliferative capacity is reduced by aging (Stenderup et al., 2003). 
Three criteria define all types of stem cells: self-renewal, multipotency and the ability to 
reconstitute a tissue in vivo. According to a recent proposal of the International Society for 
Cellular Therapy (Dominici et al., 2006), MSCs are multipotent nonhematopoietic 
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progenitors located within the stroma of the bone marrow and other organs that are 
phenotypically characterized by the expression of several markers (e.g., CD73, CD90, and 
CD105) and the lack of expression of CD14 or CD11b, CD19 or CD79┙, CD34, CD45 and 
HLA-DR surface molecules (Mrugala et al., 2009; Kastrinaki et al., 2008). Because there is no 
specific marker for MSCs, the principal criteria for identification are adherence to the plastic 
of the tissue culture flask, fibroblast-like morphology (Prockop, 1997), the prolonged 
capacity for proliferation in supportive media and the capacity to differentiate in vitro into 
cells of mesodermal origin (chondrocytes, adipocytes, osteoblasts). Furthermore, 
characteristics of MSCs are the absence of expression of typical hematopoietic antigens like 
CD34 and CD45, and the expression of surface markers like Stro-1, CD44, CD73, CD90, 
CD105 and CD166 (Pittenger et al., 1999). 
Human MSCs, which are probably responsible for normal tissue renewal, as well as for 
response to injury (Tsai et al., 2007), have been isolated from several tissues, including bone 
marrow (Kastrinaki et al., 2008; Yoo et al., 1998), periosteum (Nakahara et al., 1990), 
perichondrium (Dounchis et al., 1997), synovial membrane (De Bari et al., 2001; Fickert et al., 
2003), articular cartilage (Alsalameh et al., 2004); connective tissue of dermis and skeletal 
muscle (Young et al., 2001), peripheral blood (Villaron et al., 2004; Kuznetsov et al., 2001; 
Zvaifler et al., 2000), adipose tissue (Zuk et al., 2001 & 2002), lung (In´t Anker et al., 2003), 
liver (Le Blanc et al., 2005), amniotic fluid (You et al., 2008; Steigman & Fauza, 2007; Fauza, 
2004), placenta (Barlow et al., 2008, Steigman & Fauza, 2007; Fauza, 2004: Matikainen & 
Laine, 2005), amniotic membrane (Díaz-Prado et al., 2010a & 2010b; Alviano et al., 2007), 
umbilical cord (Baksh et al., 2007) and umbilical cord blood (Mareschi et al., 2001). Although 
bone marrow is the usual source of MSCs, umbilical cord blood is emerging as an important 
reservoir for stem cells capable of differentiation into many cell types and possessing the 
advantages of immune status and relatively unshortened telomere length (McGuckin et al., 
2005). Some countries have private and public stem cell banks from umbilical cord blood 
(UCB) for transplant programs or personal use (Samuel et al., 2008). Multipotent MSCs are a 
promising cell resource for tissue engineering and cell-based therapeutics because of their 
ability to self-renew and differentiate into specific functional cell types (Tsai et al., 2007). The 
list of tissues with the potential for tissue engineering is increasing because of recent 
progress in stem cell biology (Bianco & Robey, 2001). 
In vitro (Pittenger et al., 1999; Majumdar et al., 1998; Muraglia et al., 2000) and in vivo 
(Gronthos et al., 2003) studies of clonally-derived MSCs demonstrated that the MSC 
population consists of subsets that have different expression of markers and different 
capacities for cellular differentiation. To improve the number of MSCs isolated from a tissue 
it is frequent to use a pre-plating technique that minimizes the number of contaminating 
fibroblasts in the culture (Richler & Yaffe, 1970). Also, MSCs show phenotypic and 
functional differences depending on their tissue of origin. For example, MSCs from bone 
marrow and synovial membrane have been differentiated by their gene expression profiles 
(Djouad et al., 2005).  
Several studies have recently reported the migration of intraarticularly injected MSCs to the 
site of a cartilage injury to repair chondral defects. In a caprine model for osteoarthritis in 
which OA is induced by the complete excision of the medial meniscus and resection of the 
anterior cruciate ligament, the intraarticular injection of MSCs produced meniscus repair 
after 6 weeks; however, there was no evidence of cartilage or ligament repair (Murphy et al., 
2003). This suggests that the injected MSCs migrated to the injured meniscus, but not the 
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damaged cartilage. The intraarticular injection of MSCs into rat knees, however, showed 
mobilization of these cells towards all injured tissues, including articular cartilage; the MSCs 
contributed to tissue regeneration (Nishimori et al., 2006; Agung et al., 2006). 
In osteoarthritic knees, MSCs embedded in collagen gel were implanted into chondral 
defects and closed with periosteal membrane. After 42 weeks, arthroscopic and histological 
results were better than in osteoarthritic patients without implants, although there was no 
statistically significant improvement in clinical results (Wakitani et al., 2002). The use of 
MSCs to treat chondral lesions clinically has not been established, in part because the stages 
of chondrogenic differentiation of MSCs are not sufficiently defined. In addition, there are 
currently no protocols that ensure direct differentiation to the desired phenotype; the 
plasticity of the cells differentiated from MSCs can lead to undesirable phenotypic 
alterations (De Bari et al., 2004; Pelttari et al., 2006). 
10. Scaffolds 
The clinical outcome of the techniques described above underline the need of increase the 
quality of the synthesized repair tissue. To overcome some of the limitations of ACI, cell 
delivery supports can be used for cell transplantation. Recent research efforts have focused 
on tissue engineering as a promising approach for cartilage regeneration and repair (Kuo et 
al., 2006). Tissue engineering is a technique by which a living tissue can be reconstructed by 
associating the cells with biomaterials that provide a scaffold on which they can proliferate 
three-dimensionally, under physiological conditions (Iwasa et al., 2009). A biomaterial is any 
pharmacologically inert compound designed to be implanted or incorporated into the living 
system. Therefore cartilage tissue engineering is critically dependent on the selection of 
appropriate cells (differentiated or MSCs), suitable scaffolds for cell delivery and biological 
stimulation with chondrogenically bioactive molecules (Kuo et al., 2006). The 
transplantation of chondrocytes seeded on natural and synthetic scaffolds has been used for 
cartilage tissue engineering (Kuo et al., 2006). Regeneration of a hyaline-like repair tissue 
could be obtained after the implantation of a pre-engineering, functional cartilage tissue, 
instead of the delivery of a chondrocyte implantation (Pelttari et al., 2009). A major 
prerequisite for choosing a scaffold is the property of not producing toxic, injurious, 
carcinogenic, or immunological responses (either inflammation or rejection) in living tissue 
(Niknejad et al., 2008). New tissue regeneration should occur as the scaffold degrades, so the 
new tissue assumes the shape and size of the original scaffold. Design criteria for scaffolds 
include suitable mechanical strength and surface chemistry, ability to be processed in 
different shapes and sizes, and the ability to regulate cellular activities such as 
differentiation and proliferation (Kuo et al., 2006). Moreover, requirements for the 
biomaterials used as a scaffold include controlled biocompatibility, structurally and 
mechanically stable, permeability (allowing the exchange of nutrients and metabolites), 
suitable ligands for implanted cell attachment, must support the loading of an appropriate 
cell source to allow successful infiltration and attachment with appropriate bioactive 
molecules in order to promote cellular differentiation and maturation. Also, they must 
present readily integration with native cartilage, biodegradation into non-toxic products 
that can be replaced by host cells, initial stability and provide an excellent environment for 
cell and tissue growth and differentiation crucial to maintain cell function and development 
of new tissue. Scaffolds must also provide a stable temporary structure while cells seeded 
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within the biodegradable matrix synthesize a new and natural tissue (Frenkel & Di Cesare, 
2004). Other important factors in the design of a scaffold are pore size, porosity, adaptive 
shape, mechanical integrity, the ability to be retained at the implantation site and cost 
efficiency.  
A number of scaffolds have been developed and investigated, in vitro and in vivo, for 
potential use in tissue engineering and in particular for in vitro regeneration of cartilage 
tissues (Vinatier et al., 2009). Carries have been marketed and various tissue-engineering 
techniques have been developed using chondrocytes seeded on biological matrices (Iwasa et 
al., 2009). For cartilage tissue engineering, scaffolding has been fabricated from both natural 
and synthetic polymers (Tuli et al., 2003), such as fibrous structures, porous sponges, woven 
or non-woven meshes and hydrogels (Kuo et al., 2006). Natural biomaterials, such as fibrin, 
collagen, agarose, alginate, hyaluronic acid or chitosan (Eyrich et al., 2007; Cao & Xu, 2008; 
Mouw et al., 2005; Lisignoli et al., 2006; Nettles et al., 2002) and synthetic biomaterials, such 
as poly-lactic glycolic acid (PLGA) (Han et al., 2008) and a polymeric nanofiber (Janjanin et 
al., 2008), are used alone or in different combinations to make scaffolds. Collagen and 
hyaluronan-based matrices are among the most popular natural scaffolds in clinical use 
nowadays, since they contain natural components of the hyaline cartilage.  On the contrary, 
there is no clinical experience using scaffolds such as alginate, agarose and chitosan (Iwasa 
et al., 2009). Within each kind of biomaterial (natural and synthetic) there are many types of 
biomaterials that are being studied, with controversial results. The human amniotic 
membrane (HAM) is considered to be an important potential source for scaffolding material 
(Niknejad et al., 2008). The HAM possesses clinical considerable advantages that are not 
shared by other natural or synthetic polymers. On the other hand, HAM has abundant 
natural cartilage components, which are important in the regulation and maintenance of 
normal chondrocyte metabolism (Jin et al., 2007); this suggests that the HAM is an excellent 
candidate for use as native scaffold for cartilage tissue engineering (Niknejad et al., 2008). 
Amnion allografts are widely applied in ophthalmology, plastic surgery, dermatology, and 
gynecology (Tejwani et al., 2007; Santos et al., 2005; Rinastiti et al., 2006; Meller et al., 2000; 
Morton & Dewhurst, 1986). A recent study demonstrated the potential use of the HAM as a 
scaffold to support human chondrocyte proliferation in cell therapy to repair human OA 
cartilage (Díaz-Prado et al., 2010c). 
Experimental studies in animals with synthetic biomaterials showed disappointing results, 
since after 8 weeks of implantation, all animals suffered ulceration and loss of cartilage (Oka 
et al., 1997). The problem that arises with artificial biomaterials is that the implant is not 
interwoven with adjacent bone, leading to degradation of the recovered surface after only 2 
or 3 months (Oka et al., 1997). In a study in rabbits with a biomaterial composed of collagen 
in which chondrocytes were seeded, a good proliferation and cell phenotype maintenance 
were shown; therefore good repair results were observed (Frenkel et., 1997). One of the 
major limitations of the use of matrices is the size of the lesion (Nixon et al., 1993, Sams & 
Nixon, 1995, Sams et al., 1995). Despite the diffusion of new tissue-engineering techniques 
and the number of scaffolds that have been investigated, the ideal matrix material has not 
been identified. However, the clinical use of these materials is currently limited, mainly due 
to the risk of disease transmission and immunoreaction (Iwasa et al., 2009). 
Mechanical and biological properties of biomaterials significantly influence chondrogenesis 
and the long-term maintenance of the structural integrity of the neo-formed tissue. The 
three-dimensional nature of the scaffolds promotes maintenance of rounded cell 
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morphology and the elevated expression of glycosaminoglycans and type II collagen 
(Nettles et al., 2002; Gong et al., 2008). Other advantage is that cell delivery supports may act 
as barrier to the invasion of the graft by fibroblasts, which may otherwise induce fibrous 
repair (Frenkel et al., 1997). Indeed, the presence of ECM around cells was reported to 
increase donor cell retention at the repair site and possibly protect the cells from 
environmental factors such as inflammatory molecules (Pelttari et al., 2009). The tissue-
engineering methods with scaffolds including the arthroscopy technique are less invasive 
because there is no need to harvest periosteum (Iwasa et al., 2009). Other benefits of this 
methodology are: reduce surgical time, morbidity, and risk of periosteal hypertrophy and 
postsurgical adhesions substantially (Iwasa et al., 2009). However, scaffolding biomaterials 
have differing influences on the metabolism of host cells and, consequently, the quality of 
the tissue-engineered cartilage (Mouw et al., 2005, Jeon et al., 2007). For example, the use of 
chitosan, compared to PLGA, for cartilage tissue engineering produces a superior 
maintenance of structural integrity because the expression of type II collagen protein and 
mRNA became weaker over time in the PLGA group (Jeon et al., 2007). Scaffolds using 
hyaluronic acid are also being used with excellent clinical and histological results (Giannini 
et al., 2008). 
11. Gene therapy 
The introduction of genetic products into the field of tissue damage repair can enhance the 
process of articular cartilage restoration. The most obvious would be growth factors, 
proteinase inhibitors and cytokine antagonists. The gene therapy process involves the 
determination of the appropriate gene and cell type (chondrocytes, chondrogenic cells and 
cells of the synovial membrane) for the gene transfer, as well as the determination of the 
optimal vector to incorporate the cDNA (Trippel et al., 2004). Different anabolic factors, such 
as members of the TGF-┚3 (tumor growth factor beta 3), IGF (insulin growth factor), FGF 
(fibroblastic growth factor), and HGF (hepatocyte growth factor) superfamily, could induce 
chondrogenesis and the synthesis of ECM components, while anti-inflammatory molecules, 
such as interleukins (IL): IL-4, IL-10, Il-1Ra (IL-1 receptor antagonist), and TNFsR (tumor 
necrosis factor soluble receptor), could act as inhibitors of cartilage degradation (Gelse et al., 
2003). 
The synovial membrane seems to be useful as a target for chondroprotective therapies 
(Palmer et al., 2002). The viral transfection in vivo with the IL-1Ra gene in rheumatoid 
arthritis joints reduces the severity of the disease process in animal models (Gouze et al., 
2003). Furthermore, this technique makes possible the safe intraarticular expression of the 
IL-1Ra gene (Evans et al., 2005 & 2001). Chondrocytes and MSCs are the preferred targets 
for the induction of chondrogenesis. Using animal models, the transplantation in vivo of 
MSCs transfected with BMP-2 (bone morphogenetic protein-2) cDNA produces improved 
chondral lesion repair with a higher production of proteoglycans and type II collagen 
compared to controls (Park et al., 2006). 
12. Conclusion 
Modalities of cellular therapy to repair focal articular cartilage defects include the 
implantation of cells with chondrogenic capacity and creating access to the bone-marrow. Of 
the numerous treatments available nowadays, no technique has yet been able to consistently 
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regenerate normal hyaline cartilage. The implantation of autologous chondrocytes and 
autologous mosaicplasty induces a better quality of articular cartilage whereas the use of 
stem cell implants is in an early experimental stage at this time. Currently the autologous 
chondrocyte implantation is the most effective therapeutic alternative to repair focal 
articular cartilage lesions although this procedure is also used for patients with 
osteochondritis dissecans but not for osteoarthritis joints. On the other hand the use of 
tissue-engineered grafts based on scaffolds seems to be as effective as conventional ACI 
clinically but there are no convincing evidences that scaffold techniques allow the 
maintenance of the chondrocyte phenotype and the homogeneous distribution of the cells. 
Therefore it has not verified that the technical and theoretical advantages of scaffold 
techniques have led to the better clinical and histological results compared with 
conventional ACI. Further studies would be needed to determine whether articular cartilage 
repair with scaffolds is the most adequate alternative to ACI. 
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